CAAS Capital Management’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-38,800
Closed -$5.55M 853
2021
Q4
$5.55M Hold
38,800
0.14% 172
2021
Q3
$8.04M Hold
38,800
0.16% 133
2021
Q2
$8.24M Sell
38,800
-11,200
-22% -$2.05M 0.14% 170
2021
Q1
$9.07M Buy
+50,000
New +$9.96M 0.1% 237

Other funds holding NVAX

CAAS Capital Management's NVAX Position: Q1 2023 in Review

CAAS Capital Management sold out of Novavax (NVAX) in Q1 2023, closing a stake of 1,000,000 shares — an estimated $10.3M sold.

CAAS Capital Management first reported a position in NVAX in Q4 2021 and held it in 2 quarters. The position peaked at $10.3M in Q4 2022. 222 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

  • CAAS Capital Management reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 1,000,000 Novavax shares in Q1 2023, an estimated $10.3M.
  • CAAS Capital Management first reported a position in Novavax in Q4 2021 and held it in 2 quarters.
  • CAAS Capital Management's Novavax position peaked at $10.3M in Q4 2022.
  • 222 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.